Screening for bladder cancer: A perspective

Yair Lotan, Robert S. Svatek, Núria Malats

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Bladder cancer is the seventh most common cancer worldwide in men and the 17th in women with an overall number of 356,000 new cases of urinary bladder cancer worldwide in 2002. It is one of the most expensive cancers from diagnosis to death and the fifth most expensive cancer in terms of total medical care expenditures in the US. A screening program that resulted in detection of bladder cancer at an earlier stage, prior to muscle invasion or metastasis, could render a significant improvement in patient morbidity and overall survival. Acceptance of wide-spread screening strategies requires careful consideration of the competing risks, benefits, and costs associated with such policies. In this article, we will review the pros and cons of bladder cancer screening with a focus on cost-effectiveness and who should be screened.

Original languageEnglish (US)
Pages (from-to)13-18
Number of pages6
JournalWorld Journal of Urology
Volume26
Issue number1
DOIs
StatePublished - Feb 2008

Fingerprint

Urinary Bladder Neoplasms
Cost-Benefit Analysis
Neoplasms
Health Expenditures
Early Detection of Cancer
Neoplasm Metastasis
Morbidity
Muscles
Survival

Keywords

  • Bladder cancer screening
  • Cost-effectiveness
  • Target population

ASJC Scopus subject areas

  • Urology

Cite this

Screening for bladder cancer : A perspective. / Lotan, Yair; Svatek, Robert S.; Malats, Núria.

In: World Journal of Urology, Vol. 26, No. 1, 02.2008, p. 13-18.

Research output: Contribution to journalArticle

Lotan, Yair ; Svatek, Robert S. ; Malats, Núria. / Screening for bladder cancer : A perspective. In: World Journal of Urology. 2008 ; Vol. 26, No. 1. pp. 13-18.
@article{ab18d75ba4ae4c9385499f5af0aaade9,
title = "Screening for bladder cancer: A perspective",
abstract = "Bladder cancer is the seventh most common cancer worldwide in men and the 17th in women with an overall number of 356,000 new cases of urinary bladder cancer worldwide in 2002. It is one of the most expensive cancers from diagnosis to death and the fifth most expensive cancer in terms of total medical care expenditures in the US. A screening program that resulted in detection of bladder cancer at an earlier stage, prior to muscle invasion or metastasis, could render a significant improvement in patient morbidity and overall survival. Acceptance of wide-spread screening strategies requires careful consideration of the competing risks, benefits, and costs associated with such policies. In this article, we will review the pros and cons of bladder cancer screening with a focus on cost-effectiveness and who should be screened.",
keywords = "Bladder cancer screening, Cost-effectiveness, Target population",
author = "Yair Lotan and Svatek, {Robert S.} and N{\'u}ria Malats",
year = "2008",
month = "2",
doi = "10.1007/s00345-007-0223-2",
language = "English (US)",
volume = "26",
pages = "13--18",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Screening for bladder cancer

T2 - A perspective

AU - Lotan, Yair

AU - Svatek, Robert S.

AU - Malats, Núria

PY - 2008/2

Y1 - 2008/2

N2 - Bladder cancer is the seventh most common cancer worldwide in men and the 17th in women with an overall number of 356,000 new cases of urinary bladder cancer worldwide in 2002. It is one of the most expensive cancers from diagnosis to death and the fifth most expensive cancer in terms of total medical care expenditures in the US. A screening program that resulted in detection of bladder cancer at an earlier stage, prior to muscle invasion or metastasis, could render a significant improvement in patient morbidity and overall survival. Acceptance of wide-spread screening strategies requires careful consideration of the competing risks, benefits, and costs associated with such policies. In this article, we will review the pros and cons of bladder cancer screening with a focus on cost-effectiveness and who should be screened.

AB - Bladder cancer is the seventh most common cancer worldwide in men and the 17th in women with an overall number of 356,000 new cases of urinary bladder cancer worldwide in 2002. It is one of the most expensive cancers from diagnosis to death and the fifth most expensive cancer in terms of total medical care expenditures in the US. A screening program that resulted in detection of bladder cancer at an earlier stage, prior to muscle invasion or metastasis, could render a significant improvement in patient morbidity and overall survival. Acceptance of wide-spread screening strategies requires careful consideration of the competing risks, benefits, and costs associated with such policies. In this article, we will review the pros and cons of bladder cancer screening with a focus on cost-effectiveness and who should be screened.

KW - Bladder cancer screening

KW - Cost-effectiveness

KW - Target population

UR - http://www.scopus.com/inward/record.url?scp=39349112505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39349112505&partnerID=8YFLogxK

U2 - 10.1007/s00345-007-0223-2

DO - 10.1007/s00345-007-0223-2

M3 - Article

C2 - 18030473

AN - SCOPUS:39349112505

VL - 26

SP - 13

EP - 18

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 1

ER -